Anavex's phase 2b/3 trial of blarcamesine (anavex®2-73) in patients with alzheimer's disease shows robust clinical efficacy and slows neurodegeneration

Significant reduction of amyloid beta biomarkers of alzheimer's pathology significant reduction of amyloid beta biomarkers of alzheimer's pathology

AVXL Ratings Summary

AVXL Quant Ranking